IRIS
MAZZASCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.580
NA - Nord America 1.456
AS - Asia 731
AF - Africa 28
SA - Sud America 5
OC - Oceania 4
Totale 3.804
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.443
IT - Italia 568
SG - Singapore 358
IE - Irlanda 326
CN - Cina 289
SE - Svezia 270
DE - Germania 110
FR - Francia 69
AT - Austria 53
FI - Finlandia 45
IN - India 41
GB - Regno Unito 30
CI - Costa d'Avorio 26
BE - Belgio 25
CZ - Repubblica Ceca 25
TR - Turchia 18
NL - Olanda 14
CA - Canada 13
RU - Federazione Russa 12
UA - Ucraina 8
LU - Lussemburgo 6
HK - Hong Kong 5
AU - Australia 4
IR - Iran 4
KR - Corea 4
LT - Lituania 3
AR - Argentina 2
BG - Bulgaria 2
BR - Brasile 2
CH - Svizzera 2
DK - Danimarca 2
ID - Indonesia 2
IL - Israele 2
MD - Moldavia 2
PL - Polonia 2
AZ - Azerbaigian 1
EC - Ecuador 1
ES - Italia 1
HU - Ungheria 1
JP - Giappone 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MK - Macedonia 1
MT - Malta 1
NO - Norvegia 1
PH - Filippine 1
RS - Serbia 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 3.804
Salva come PNG Salva come JPEG
Città #
Dublin 323
Chandler 313
Singapore 280
Parma 140
Boardman 133
Ashburn 132
Ann Arbor 126
Shanghai 94
New York 58
Vienna 53
Bologna 51
Beijing 50
Bremen 41
Princeton 38
Milan 36
Helsinki 35
Munich 32
Dearborn 31
Marseille 31
Abidjan 26
Nanjing 24
Brussels 23
West Jordan 22
Rome 21
Los Angeles 19
Verona 18
Des Moines 17
Brno 15
Rio Saliceto 15
Wilmington 15
Chicago 14
Santa Clara 13
Frankfurt am Main 12
Fremont 11
Jinan 11
Pune 11
Dallas 10
Torrile 10
Izmir 9
Sorbolo 9
Trento 9
Ardea 8
Falls Church 8
Guangzhou 8
London 8
Reggio Emilia 8
San Mateo 8
Amsterdam 7
Hangzhou 7
Hefei 7
Nanchang 7
Boston 6
Houston 6
Kocaeli 6
Modena 6
Olomouc 6
Bolzano 5
Hebei 5
Jiaxing 5
Kunming 5
Norwalk 5
Redwood City 5
Seattle 5
Toronto 5
Verdellino 5
Woodbridge 5
Zhengzhou 5
Assago 4
Busto Arsizio 4
Catania 4
Chiari 4
Florence 4
Grafing 4
Kochi 4
Kolkata 4
Montreal 4
Naples 4
Shenyang 4
Trieste 4
Turin 4
Wayne 4
Atlanta 3
Brescia 3
Changsha 3
Collecchio 3
Genova 3
Kyiv 3
Lanzhou 3
Lonato 3
Melbourne 3
Ottawa 3
San Giuliano Milanese 3
Scandiano 3
Tianjin 3
Washington 3
Alcamo 2
Bagnolo in Piano 2
Bali 2
Bhubaneswar 2
Brooklyn 2
Totale 2.600
Salva come PNG Salva come JPEG
Nome #
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 122
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 117
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 117
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 100
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 94
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 94
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 89
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 87
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 85
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 79
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 76
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 76
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 75
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 73
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 73
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 71
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 70
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 68
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 67
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 66
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 66
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 66
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 66
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 64
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 64
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 64
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 60
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 60
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 55
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 53
227P Sexual dimorphism in immune profile of early and advanced NSCLC 50
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 50
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 49
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 48
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 47
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 45
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 44
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 43
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 42
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 42
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 41
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 41
The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies 41
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 38
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 38
The radiological appearances of lung cancer treated with immunotherapy: a review 37
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 37
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 37
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study 35
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 35
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 33
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 32
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 31
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 30
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 28
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 25
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 25
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 24
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 24
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 24
Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9 23
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 22
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer 22
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 21
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC? 21
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 21
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 21
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 20
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 20
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 19
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 18
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 18
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 18
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 17
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model 16
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 15
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 15
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review 15
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 15
Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A 12
Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study 12
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 12
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 12
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 11
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 11
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 11
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 10
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report 10
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 10
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 9
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study 9
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 9
Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade 8
The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. 7
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 5
Totale 3.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.463
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.463
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020169 0 0 0 0 15 33 19 15 10 60 10 7
2020/2021251 10 11 10 23 33 33 16 18 24 17 35 21
2021/2022272 13 13 15 19 5 12 60 10 6 10 21 88
2022/20231.306 121 129 72 109 143 143 38 73 391 7 56 24
2023/2024876 33 60 28 36 110 157 97 36 62 80 49 128
2024/2025866 92 177 226 197 174 0 0 0 0 0 0 0
Totale 3.948